ENVISIONING AN END TO NEURODEGENERATIVE DISEASES

ENVISIONING AN END TO NEURODEGENERATIVE DISEASES

Eikonizo is developing life-changing therapies by creating brain-penetrant small molecules to accelerate the identification of therapeutics

Therapeutics for neurodegenerative disease

Eikonizo is developing life-changing therapies by creating brain-penetrant small molecules and deploying in vivo target engagement techniques to accelerate the identification of therapeutics.

HDAC6 inhibitors
disease-modifying
IMAGING AGENTS
NOVEL TARGET
What we do

Our approach

Our Lead Program

Eikonizo is developing brain-penetrant small molecules to slow or stop ALS

Our Lead Program

Eikonizo is developing brain-penetrant molecule, inhibitors including Alzheimer's disease
Read More

Mechanistic Rationale

HDAC6 inhibitor treatment will improve axonal transport and reduce protein aggregates to help neurons survive

Mechanistic Rationale

HDAC6 inhibitor treatment will improve axonal transport and reduce protein aggregates to help neurons survive
Read More

Supporting Literature

Compelling evidence from multiple research groups supports Eikonizo’s approach for using HDAC6 inhibitors

Supporting Literature

Multiple research groups support Eikonizo’s approach for using HDAC6 inhibitors
Read More
electron microscopic view
Mechanistically Based

Therapeutic Development

Our brain-penetrant small molecules inhibit HDAC6, an enzyme that modifies key proteins involved in amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease (AD) pathology. Inhibiting HDAC6 will preserve axonal transport and stop or slow the progression of ALS and also help neuron health in other neurodegenerative disease. Emerging data suggest HDAC6 inhibition could also prevent pathological tau phosphorylation and downstream aggregation (tangles) in AD and ‘chemo-brain’.

Our Mission

De-risk therapeutic approaches to neurodegeneration

Eikonizo is developing life-changing therapies by creating brain-penetrant small molecules and deploying in vivo target engagement techniques to accelerate the identification of therapeutics. Our first program is focused on a disease-modifying therapeutic for neurodegenerative diseases.

HDAC6 inhibitor treatment will preserve axonal transport and stop or slow the progression of AD and ALS

Our Location